NDAORALFOR SUSPENSIONPriority Review
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
AQNEURSA (levacetylleucine) by IntraBio is p-glycoprotein inhibitors [moa]. First approved in 2024.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AQNEURSA (levacetylleucine) is an oral suspension small molecule approved in September 2024 that acts as a P-glycoprotein inhibitor to enhance drug delivery across biological barriers. The product is indicated for neurological conditions where transporter-mediated drug efflux limits therapeutic efficacy. It represents a novel mechanism for enhancing CNS bioavailability of co-administered agents.
Growth10.7 years to LOE
Early-stage commercial lifecycle with high growth potential; brand teams will focus on market development and physician education in specialized neurology segments.
Mechanism of Action
P-Glycoprotein Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T)
Ataxia-Telangiectasia (A-T)
Career Relevance
Working on AQNEURSA offers entry into an innovative, mechanism-first product with limited competition and a high-stakes commercial launch environment requiring strong payer and physician engagement. The specialized neurology focus and novel P-gp inhibitor mechanism provide differentiated career development in rare/orphan disease commercialization and transporter biology.
Brand Manager
Worked on AQNEURSA at IntraBio? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.